![Quiver Logo](/static/img/logo-icon.png)
![AYTU logo](https://quiver-logos.s3.us-east-2.amazonaws.com/aytu.png)
AYTU BioPharma, Inc. Common Stock
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complimentary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. AR101/enzastaurin has received Orphan Drug designation from the FDA. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which it generates maximum revenue from the Rx segment.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view AYTU Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Recent trades of AYTU by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by AYTU's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Recent insights relating to AYTU
Recent picks made for AYTU stock on CNBC
ETFs with the largest estimated holdings in AYTU
Flights by private jets registered to AYTU
![Quiver Logo](/static/img/logo-icon.png)